Table 1.

Post-PCV-13 antibody concentration and fold-rise in antibody concentration by time since PPV receipt and CD4 count.

	By Years Since Pneumovax Receipt				By CD4 Count at Vaccination
	1-3 years (n=42)	>3 years (n=54)	unadjusted p value	adjusted p value	<500 cells/mm3 (n=37)	>500 cells/mm3 (n=59)	unadjusted p value	adjusted p value
Serotype 3
Post Booster GMC (95% CI)	0.26 (0.17-0.41)	0.31 (0.22-0.44)	NS	NS	0.16 (0.11-0.25)	0.41 (0.30-0.57)	0.0008	0.01
Fold-rise geometric mean (95% CI)	3.24 (2.16-4.87)	4.32 (3.18-5.89)	NS	NS	3.17 (2.14-4.70)	4.28 (3.11-5.90)	NS	NS
Serotype 6A
Post Booster GMC (95% CI)	2.27 (1.43-3.61)	1.82 (1.40-2.37)	NS	NS	1.74 (1.19-2.55)	2.19 (1.58-3.05)	NS	NS
Fold-rise geometric mean (95% CI)	3.61 (2.46-5.29)	3.28 (2.40-4.49)	NS	NS	3.88 (2.48-6.07)	3.16 (2.39-4.17)	NS	NS
Serotype 7F
Post Booster GMC (95% CI)	1.00 (0.60-1.68)	1.25 (0.84-1.87)	NS	NS	0.81 (0.48-1.37)	1.41 (0.96-2.08)	NS (0.09)	NS
Fold-rise geometric mean (95% CI)	4.01 (2.70-5.94)	8.04 (4.8-13.47)	0.043	NS (0.06)	6.22 (3.96-9.76)	5.75 (3.54-9.34)	NS	NS
Serotype 19A
Post Booster GMC (95% CI)	2.97 (2.08-4.24)	3.55 (2.54-4.98)	NS	NS	2.34 (1.54-3.56)	4.06 (3.04-5.43)	0.03	NS (0.07)
Fold-rise geometric mean (95% CI)	1.99 (1.55-2.56)	2.69 (2.00-3.61)	NS	NS (0.09)	2.00 (1.49-2.68)	2.62 (2.00-3.42)	NS	NS

GMC = geometric mean concentration. CI = confidence interval. NS = nonsignificant. Adjusted p values were from multivariate regression models including the following covariates: age, gender, race, statin use, AIDS diagnosis, history of pneumonia, diabetes, history of homelessness, current smoking status, and hepatitis C coinfection. Of note, serotypes 3, 7F, and 19A are included in both PCV-13 and PPV, but 6A is only in PCV-13.